TBA-354: Phase I started

The not-for-profit Global Alliance for TB Drug Development began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate single ascending doses of 10, 25, 60, 150, 400 and 1,000 mg oral TBA...